Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

-0.43 (-2.38%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
443,600 shs
Average Volume
899,166 shs
Market Capitalization
$1.60 billion
P/E Ratio
Dividend Yield
Price Target

Avadel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
27.8% Upside
$22.57 Price Target
Short Interest
11.47% of Shares Sold Short
Dividend Strength
News Sentiment
1.06mentions of Avadel Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.46) to $0.83 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.24 out of 5 stars

Medical Sector

310th out of 907 stocks

Pharmaceutical Preparations Industry

139th out of 422 stocks

AVDL stock logo

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Stock Price History

AVDL Stock News Headlines

Avadel Pharmaceuticals plc
At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
Avadel Pharmaceuticals plc (AVDL)
At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
AVDL Apr 2024 15.000 call
AVDL Apr 2024 25.000 call
AVDL Apr 2024 10.000 put
AVDL Mar 2024 5.000 put
Avadel Pharmaceuticals Q4 2023 Earnings Preview
AVDL Jan 2025 20.000 call
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$27.96 million
Book Value
$0.98 per share


Free Float
Market Cap
$1.60 billion

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Gregory J. Divis Jr. (Age 57)
    CEO & Director
    Comp: $753.69k
  • Mr. Thomas S. McHugh (Age 59)
    Senior VP, Principal Financial and Accounting Officer & CFO
    Comp: $526k
  • Mr. Richard J. Kim (Age 55)
    Chief Commercial Officer
    Comp: $548.44k
  • Mr. Jerad G. Seurer
    General Counsel & Company Secretary
  • Mr. Gregory J. Davis (Age 59)
    VP of Corporate and Business Development
  • Mr. Mark W. Elrod
    Vice President of Sales
  • Ms. Angie Woods
    Vice President of People & Culture
  • Dr. Jordan S. Dubow M.D. (Age 45)
    Comp: $727.93k
  • Dr. Jason M. Vaughn
    Senior Vice President of Technical Operations
  • Ms. Jennifer Gudeman PharmD
    Senior Vice President of Medical & Clinical Affairs

AVDL Stock Analysis - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price target for 2024?

7 Wall Street analysts have issued 12 month target prices for Avadel Pharmaceuticals' stock. Their AVDL share price targets range from $16.00 to $29.00. On average, they expect the company's share price to reach $22.57 in the next year. This suggests a possible upside of 27.8% from the stock's current price.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2024?

Avadel Pharmaceuticals' stock was trading at $14.12 at the beginning of the year. Since then, AVDL stock has increased by 25.1% and is now trading at $17.66.
View the best growth stocks for 2024 here

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AVDL earnings forecast

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Monday, March, 4th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.04. The firm earned $19.45 million during the quarter, compared to analysts' expectations of $17.41 million. During the same quarter in the previous year, the company earned ($0.44) earnings per share.

What ETFs hold Avadel Pharmaceuticals' stock?

ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and AdvisorShares Dorsey Wright ADR ETF (AADR).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (4.39%), Wealth Effects LLC (2.50%), Investors Asset Management of Georgia Inc. GA ADV (0.10%) and Claro Advisors LLC (0.01%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh.
View institutional ownership trends

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVDL) was last updated on 4/25/2024 by Staff

From Our Partners